by GlobeNewsWire | Sep 26, 2015 | Globe Newswire
VIENNA, Austria and BERKELEY, Calif., Sept. 26, 2015 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the presentation of updated, interim safety and efficacy data from an ongoing Phase 1b clinical trial of its novel immunotherapy, CRS-207,...